Rotate the site of injection to avoid irritation or sterile abscess formation with repeat administration. Intramuscular Depot injection (fluphenazine decanoate or . PACKAGE LEAFLET: INFORMATION FOR THE USER. Modecate® 25mg/ml Injection fluphenazine decanoate. Is this leaflet hard to see or read? Phone . ADMINISTRATION). Fluphenazine decanoate is not indicated for the management of severely agitated psychotic patients or psychoneurotic.
|Published (Last):||23 April 2013|
|PDF File Size:||5.29 Mb|
|ePub File Size:||6.9 Mb|
|Price:||Free* [*Free Regsitration Required]|
Some hyperprolactinemic women with normal menstruation may have an increased number of anovulatory cycles, which may result in subfertility. Increases risk of arrhythmias and conduction defects.
Drospirenone; Ethinyl Estradiol; Levomefolate: According to the manufacturer, concurrent use of citalopram with other drugs that prolong the QT interval pacakge not recommended. A dose reduction of one or both drugs may be needed. Theoretically, fluphenazine may increase the risk of QT prolongation if coadministered with drugs with a possible risk for QT prolongation. Hydroxychloroquine increases the QT interval and should not be administered with other drugs known to prolong the QT interval.
Piperazine phenothiazine antipsychotic; 2 mg orally equivalent to mg of oral chlorpromazine, the prototype antipsychotic; depot IM injections i. Bedaquiline has been reported to prolong the QT interval. The use of latex gloves has been recommended when administering the oral liquid or injectable forms of this drug. Ethinyl Estradiol; Ethynodiol Diacetate: Investigators from a separate study reported that the risk of vecanoate all cause ihsert in the conventional antipsychotic group was comparable to and possibly greater than the risk of death in the atypical antipsychotic group.
Modecate Injection 25mg/ml
The likelihood of these pharmacodynamic interactions varies based upon the individual properties of the coadministered antipsychotic agent, with low-potency agents e. Depending fluphenazne the specific agent, additive anticholinergic effects may also be seen; clinicians should note that antimuscarinic effects may be seen not only on GI smooth muscle, but also on bladder function, the eye, and temperature regulation. Wear gloves and avoid contact with skin and clothing.
Therefore, appropriate monitoring and dose adjustment may be necessary. Fluphenazine is contraindicated for use in patients with known hypersensitivity to fluphenazine or other phenothiazine hypersensitivity. For more information, contact the registry at https: Monitor serum concentrations and clinical condition. Fluphenazine should be used with caution in patients with prostatic hypertrophy, closed-angle glaucoma, paralytic ileus, or urinary retention because the drug exhibits anticholinergic activity that can exacerbate these conditions.
Find out more here. Examples include certain anti-arrhythmics, such as those of Class 1A such as quinidine, disopyramide and procainamide and Class III such as amiodarone and sotaloltricyclic antidepressants such as amitriptyline ; certain tetracyclic antidepressants such as maprotiline ; certain antipsychotic medications such as phenothiazines and pimozide ; certain antihistamines such as terfenadine ; lithium, quinine, pentamidine and sparfloxacin.
fluphenaxine Skin rashes, hypersensitivity and anaphylactic reactions have occasionally been reported. Moderate Phenothiazines are CNS depressant drugs that may have cumulative effects when administered concurrently and they should be used cautiously with anxiolytic, sedative, and hypnotic type drugs, such as the benzodiazepines.
Phenothiazines including fluphenazine, perphenazine, prochlorperazine, and trifluoperazine are associated with a possible risk for QT prolongation.
Moderate Phenothiazines can potentiate the CNS-depressant action of other drugs such as general anesthetics. Atomoxetine and fluphenazine are considered drugs with a possible risk of torsade de pointes TdP. Overdose and treatment CNS depression is characterized by deep, unarousable sleep and possible coma, hypotension or hypertension, extrapyramidal symptoms, dystonia, abnormal involuntary muscle movements, agitation, seizures, arrhythmias, ECG changes, hypothermia or hyperthermia, and autonomic nervous system dysfunction.
The initial total daily dose is 2. Phenothiazines may impair body temperature regulation. Regulate body temperature as needed. Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as phenothiazines.
Additionally, sleep-related behaviors, such as sleep-driving, are more likely to occur during concurrent use of other CNS depressants than with the use of sedatives alone. In addition, cabergoline, a dopamine agonist, can diminish the effectiveness of dopamine antagonists such as the phenothiazines.
If a phenothiazine and carbamazepine must be used together, dosage adjustments of the phenothiazine may be required. Intramuscular Depot injection fluphenazine decanoate or fluphenazine enanthate: The increase in QTc is approximately 10 milliseconds at doses of mg twice daily the FDA-approved dose and up to 25 milliseconds at doses of mg twice daily. Concomitant administration of phenothiazines and activated charcoal dietary supplements is not recommended.